Escend Pharmaceuticals, Inc., a privately held company focused on the development of small molecule therapeutics for oncology orphan diseases, announced that the United States Food and Drug Administration has cleared its investigational new drug application for its lead drug candidate, ES-3000 for a Phase I clinical trial in relapsed or refractory acute myeloid leukemia.
July 15, 2022
· 2 min read